BMS Positions Breyanzi for Another Indication as LOE Woes Mount
Bristol Myers Squibb (BMS) announced positive mid-stage results in marginal zone lymphoma for its CAR T cell therapy, Breyanzi, potentially leading to a new indication.
The study revealed that Breyanzi met its primary efficacy endpoint, showing a statistically significant and clinically meaningful overall response rate while achieving a durable response profile with no new safety concerns. Breyanzi has now demonstrated strong clinical benefits in five cancer types, reinforcing the drug’s best-in-class and best-in-disease profile.
With its robust presence in the region through sites in Seattle and Bothell, BMS continues to drive innovation in Washington state.